Evidence map›Paper›PMID 30997946›Full record

ArticleHuman mutation2019

Response to: Concern regarding classification of germlineTP53 variants as likely pathogenic.

Kelvin C de Andrade, Megan N Frone, Talia Wegman-Ostrosky, Payal P Khincha, Jung Kim, Amina Amadou, Karina M Santiago, Fernanda P Fortes, Nathanaël Lemonnier, Lisa Mirabello and 5 more

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Human mutation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Kelvin C de AndradeDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Megan N FroneDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Talia Wegman-OstroskyDivision of Research, National Cancer Institute, Mexico City, Mexico.
Payal P KhinchaDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Jung KimDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-6274-2841
Amina AmadouDepartment of Prevention and Therapy of Chronic Diseases, Team Tumor Molecular Pathology and Biomarkers, Institute for Advanced Biosciences, Inserm U 1209, UMR 5309 Université Grenoble Alpes, Site Santé, Allée des Alpes, 38700, La Tronche, France.
Karina M SantiagoDepartment of Oncogenetics, International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.
Fernanda P FortesDepartment of Oncogenetics, International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.
Nathanaël LemonnierDepartment of Prevention and Therapy of Chronic Diseases, Team Tumor Molecular Pathology and Biomarkers, Institute for Advanced Biosciences, Inserm U 1209, UMR 5309 Université Grenoble Alpes, Site Santé, Allée des Alpes, 38700, La Tronche, France.
Lisa MirabelloDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Douglas R StewartDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Pierre HainautDepartment of Prevention and Therapy of Chronic Diseases, Team Tumor Molecular Pathology and Biomarkers, Institute for Advanced Biosciences, Inserm U 1209, UMR 5309 Université Grenoble Alpes, Site Santé, Allée des Alpes, 38700, La Tronche, France.
Luiz P KowalskiHead and Neck Surgery and Otorhinolaryngology Department, A.C. Camargo Cancer Center, São Paulo, Brazil.
Sharon A SavageDivision of Cancer Epidemiology and Genetics, Department of Health and Human Services, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Maria I AchatzOncogenetics Unit, Oncology Center, Sírio-Libanês Hospital, São Paulo, Brazil.

Funding

Division of Cancer Epidemiology and Genetics, National Cancer Institute Intramural Research Program
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Li-Fraumeni SyndromeGerm CellsGerm-Line MutationHumansPrevalenceTumor Suppressor Protein p53TP53 protein, humanTumor Suppressor Protein p53gnomADLi-Fraumeni syndromeprevalenceTP53variant classification

Identifiers

PMID30997946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.